Targeted Therapies in Oncology Staff | Authors


Larotrectinib Excites in TRK Fusion Cancers for Both Adult and Pediatric Patients

April 27, 2018

When findings of larotrectinib, a pan-TRK inhibitor co-developed by Bayer and Loxo Oncology, that generated significant excitement for the treatment of both adult and pediatric patients with TRK fusion cancers, were presented during the 2017 ASCO Annual Meeting, the small molecule was lauded as a future standard of care for patients with advanced solid tumors harboring a TRK fusion.